Benoît Brilland
@benoitbrilland.bsky.social
MD, PhD | Nephrology, Immunology | #ANCA #glomerulonephritis #transcriptomics | @maineanjoureg.bsky.social
Pinned
Next International #Vasculitis Workshop host @anzvasc.bsky.social is now on Bluesky! See key dates below ⬇️
Using kidney transcriptomics, we identified a signature predicting renal survival in #ANCA #vasculitis, outperforming histopathology and opening the way to precision medicine. Thank you @asnpublications.bsky.social for highlighting our work... and for making the article 🔓 OPEN ACCESS 🔓 for 1 month!!
Featuring this year's #ASNJASN Trainee of the Year's award-winning manuscript: "Identification of Renal Transcripts Associated with Kidney Function and Prognosis in ANCA-Associated Vasculitis"
kidney.pub/JASN0779
@benoitbrilland.bsky.social @maineanjoureg.bsky.social
kidney.pub/JASN0779
@benoitbrilland.bsky.social @maineanjoureg.bsky.social
November 7, 2025 at 9:45 PM
Using kidney transcriptomics, we identified a signature predicting renal survival in #ANCA #vasculitis, outperforming histopathology and opening the way to precision medicine. Thank you @asnpublications.bsky.social for highlighting our work... and for making the article 🔓 OPEN ACCESS 🔓 for 1 month!!
Honored that our work on renal transcriptomics in #ANCA -associated #vasculitis was selected for the #ASNJASN Trainee of the Year award. Very proud to represent the @maineanjoureg.bsky.social and @chuangers.bsky.social !
The 2025 #ASNJASN #ASNCJASN and #ASNKidney360 Trainees of the Year are Benoit Brilland, Thomas Bais, and Yuhei Noda! This prize celebrates the best article submitted to each journal by a trainee as the first author.
See more about the contest and this year's winners: kidney.pub/TraineeOf...
See more about the contest and this year's winners: kidney.pub/TraineeOf...
November 7, 2025 at 9:45 PM
Honored that our work on renal transcriptomics in #ANCA -associated #vasculitis was selected for the #ASNJASN Trainee of the Year award. Very proud to represent the @maineanjoureg.bsky.social and @chuangers.bsky.social !
Using kidney transcriptomics, we identified a robust 12-gene signature predicting renal survival in #ANCA #vasculitis, outperforming histopathology, and opening the way to precision medicine. Thank you for the highlight @asnpublications.bsky.social !
Large-scale kidney transcriptomics identified a 12-gene signature, including CLU and C3, predicting kidney failure in ANCA-associated vasculitis. Read more in #ASNJASN: kidney.pub/JASN0779
@benoitbrilland.bsky.social
@benoitbrilland.bsky.social
September 9, 2025 at 6:50 AM
Using kidney transcriptomics, we identified a robust 12-gene signature predicting renal survival in #ANCA #vasculitis, outperforming histopathology, and opening the way to precision medicine. Thank you for the highlight @asnpublications.bsky.social !
Reposted by Benoît Brilland
Ex vivo #CRISPR-Cas9 knock out PR3 autoantigen in HSPCs prevents PR3-ANCA-driven neutrophil activation while preserving immune function. While aHSCT would still be required, this opens the door to sustained, drug-free remission in PR3 #ANCA #vasculitis! doi.org/10.1016/j.ki... @kidneyint.bsky.social
April 25, 2025 at 2:06 PM
Ex vivo #CRISPR-Cas9 knock out PR3 autoantigen in HSPCs prevents PR3-ANCA-driven neutrophil activation while preserving immune function. While aHSCT would still be required, this opens the door to sustained, drug-free remission in PR3 #ANCA #vasculitis! doi.org/10.1016/j.ki... @kidneyint.bsky.social
Reposted by Benoît Brilland
This new study shifts the focus from anti-MPO IgG to IgM in #ANCA -associated #vasculitis. IgM autoantibodies not only trigger potent complement activation but also dominate the autoreactive memory B cell pool—revealing a new pathogenic paradigm. Potential implications ⬇️
April 1, 2025 at 12:49 PM
This new study shifts the focus from anti-MPO IgG to IgM in #ANCA -associated #vasculitis. IgM autoantibodies not only trigger potent complement activation but also dominate the autoreactive memory B cell pool—revealing a new pathogenic paradigm. Potential implications ⬇️
Reposted by Benoît Brilland
Targeting endothelial ferroptosis protects kidneys in #ANCA -associated #vasculitis, while systemic inhibition increases inflammation. This is why cell-specific therapies should be prioritised over blanket treatments! @kidneyint.bsky.social doi.org/10.1016/j.ki...
April 1, 2025 at 1:08 PM
Targeting endothelial ferroptosis protects kidneys in #ANCA -associated #vasculitis, while systemic inhibition increases inflammation. This is why cell-specific therapies should be prioritised over blanket treatments! @kidneyint.bsky.social doi.org/10.1016/j.ki...
US 🇺🇸 nephrologists, immunologists, pathologists (et al.): there is a place for each of you in France 🇫🇷 … and especially in Angers if you like #vasculitis! www.nature.com/articles/d41...
75% of US scientists who answered Nature poll consider leaving
More than 1,600 readers answered our poll; many said they were looking for jobs in Europe and Canada.
www.nature.com
March 29, 2025 at 9:42 PM
US 🇺🇸 nephrologists, immunologists, pathologists (et al.): there is a place for each of you in France 🇫🇷 … and especially in Angers if you like #vasculitis! www.nature.com/articles/d41...
Reposted by Benoît Brilland
Kidney transplantation significantly improves survival in #ANCA-associated #vasculitis patients with end-stage kidney disease: 53% lower mortality risk. Our analysis from the french REIN registry ⬇️
Kidney #Transplantation Improves Survival in Antineutrophil Cytoplasmic Antibody–Associated #ANCA #Vasculitides With End-Stage Kidney Disease #ESKD
#VisualAbstract by @DrPSVali
www.kireports.org/ar...
@benoitbrilland.bsky.social
#VisualAbstract by @DrPSVali
www.kireports.org/ar...
@benoitbrilland.bsky.social
March 24, 2025 at 1:27 PM
Kidney transplantation significantly improves survival in #ANCA-associated #vasculitis patients with end-stage kidney disease: 53% lower mortality risk. Our analysis from the french REIN registry ⬇️
Kidney transplantation significantly improves survival in #ANCA-associated #vasculitis patients with end-stage kidney disease: 53% lower mortality risk. Let's improve access to #KidneyTransplant! Read more in our analysis from the french REIN registry doi.org/10.1016/j.ek...
February 26, 2025 at 10:18 PM
Kidney transplantation significantly improves survival in #ANCA-associated #vasculitis patients with end-stage kidney disease: 53% lower mortality risk. Let's improve access to #KidneyTransplant! Read more in our analysis from the french REIN registry doi.org/10.1016/j.ek...
Welcome on Bluesky! @brixsilke.bsky.social @odlerb.bsky.social @thkc.bsky.social @paradise-project.bsky.social. I have included you in the « vasculits lovers » starter pack go.bsky.app/HFADD3c
January 31, 2025 at 2:54 PM
Welcome on Bluesky! @brixsilke.bsky.social @odlerb.bsky.social @thkc.bsky.social @paradise-project.bsky.social. I have included you in the « vasculits lovers » starter pack go.bsky.app/HFADD3c
Next International #Vasculitis Workshop host @anzvasc.bsky.social is now on Bluesky! See key dates below ⬇️
January 21, 2025 at 5:18 PM
Next International #Vasculitis Workshop host @anzvasc.bsky.social is now on Bluesky! See key dates below ⬇️
Reposted by Benoît Brilland
PEXIVAS post-hoc: no effect of reduced GC dose on kidney recovery in #ANCA #vasculitis. Faster kidney recovery with PLEX but not sustained beyond 3 months (better for subgroup GFR 15-30?). Real PLEX effect vs convection effect? @kronbichlerlab.bsky.social www.kidney-international.org/article/S008...
January 8, 2025 at 4:31 PM
PEXIVAS post-hoc: no effect of reduced GC dose on kidney recovery in #ANCA #vasculitis. Faster kidney recovery with PLEX but not sustained beyond 3 months (better for subgroup GFR 15-30?). Real PLEX effect vs convection effect? @kronbichlerlab.bsky.social www.kidney-international.org/article/S008...
Reposted by Benoît Brilland
Infection is the top cause of death in #ANCA -associated #vasculitis, mostly during remission. Death certificates misreport causes, linking EHRs improves accuracy. We need to reduce infection risks through better immunosuppressive therapies www.sciencedirect.com/science/arti...
January 6, 2025 at 3:25 PM
Infection is the top cause of death in #ANCA -associated #vasculitis, mostly during remission. Death certificates misreport causes, linking EHRs improves accuracy. We need to reduce infection risks through better immunosuppressive therapies www.sciencedirect.com/science/arti...
Reposted by Benoît Brilland
In #ANCA #vasculitis, 27% patients rated their health better or worse (≥ 20 PGA points) than their physicians did. This discordance highlights the need to address patients' perspectives to improve communication, shared decision-making, and care outcomes. pubmed.ncbi.nlm.nih.gov/39671122/
December 17, 2024 at 2:29 PM
In #ANCA #vasculitis, 27% patients rated their health better or worse (≥ 20 PGA points) than their physicians did. This discordance highlights the need to address patients' perspectives to improve communication, shared decision-making, and care outcomes. pubmed.ncbi.nlm.nih.gov/39671122/
Reposted by Benoît Brilland
This study (aacrjournals.org/cancerimmuno...) shows that, in tumor-bearing mice, C5aR blockade boosts anti-PD1 efficacy by enhancing #antitumor immunity. Could these benefits translate to reducing long-term treatment-related adverse events in our #ANCA #vasculitis patients?
The C5a/C5aR1 axis promotes migration of tolerogenic dendritic cells to lymph nodes, impairing the anticancer immune response
Abstract. The precise mechanisms by which the complement system contributes to the establishment of an immunosuppressive tumor microenvironment (TME) and promotes tumor progression remain unclear. In ...
aacrjournals.org
December 16, 2024 at 8:25 PM
This study (aacrjournals.org/cancerimmuno...) shows that, in tumor-bearing mice, C5aR blockade boosts anti-PD1 efficacy by enhancing #antitumor immunity. Could these benefits translate to reducing long-term treatment-related adverse events in our #ANCA #vasculitis patients?
Reposted by Benoît Brilland
First AI-driven model for grading #ANCA -associated #glomerulonephritis lesions achieves 93% accuracy. Grad-CAM heatmaps align with pathologists’ focus, enhancing prognosis reliability. Bonus: the heatmaps look like colorful PET scans of glomeruli! www.kireports.org/article/S246...
December 12, 2024 at 6:18 PM
First AI-driven model for grading #ANCA -associated #glomerulonephritis lesions achieves 93% accuracy. Grad-CAM heatmaps align with pathologists’ focus, enhancing prognosis reliability. Bonus: the heatmaps look like colorful PET scans of glomeruli! www.kireports.org/article/S246...
Reposted by Benoît Brilland
Infections affect >50% of #ANCA -associated #vasculitis patients, with risk factors including diabetes, ESKD, kidney/lung involvement and treatment (methylprednisolone pulses, CYC, PLEX). Main site: respiratory system. Early risk management is crucial. doi.org/10.1016/j.au...
Redirecting
doi.org
December 10, 2024 at 1:47 PM
Infections affect >50% of #ANCA -associated #vasculitis patients, with risk factors including diabetes, ESKD, kidney/lung involvement and treatment (methylprednisolone pulses, CYC, PLEX). Main site: respiratory system. Early risk management is crucial. doi.org/10.1016/j.au...
Reposted by Benoît Brilland
Brace yourself, next Vasculitis Workshop is coming! Key dates:
✅ Abstract submission: 28 March - 19 September 2025
✅ Workshop dates: 21 - 25 February 2026
📍 Melbourne, Australia
vasculitis-melbourne2026.com
✅ Abstract submission: 28 March - 19 September 2025
✅ Workshop dates: 21 - 25 February 2026
📍 Melbourne, Australia
vasculitis-melbourne2026.com
IVW 2026 | 22nd International Vasculitis Workshop
Join the 22nd International Vasculitis Workshop, a leading event dedicated to advancing research, treatment, and understanding of vasculitis. Connect with global experts, researchers, and practitioner...
vasculitis-melbourne2026.com
December 5, 2024 at 1:46 PM
Brace yourself, next Vasculitis Workshop is coming! Key dates:
✅ Abstract submission: 28 March - 19 September 2025
✅ Workshop dates: 21 - 25 February 2026
📍 Melbourne, Australia
vasculitis-melbourne2026.com
✅ Abstract submission: 28 March - 19 September 2025
✅ Workshop dates: 21 - 25 February 2026
📍 Melbourne, Australia
vasculitis-melbourne2026.com
Reposted by Benoît Brilland
Bonjour, bonjour, The Conversation France arrive sur Bluesky ! Ici, pas de breaking news tapageuses ni de buzz éphémères : on mise sur le fond, avec des articles écrits par des chercheurs et chercheuses qui savent de quoi ils parlent, en collaboration avec notre équipe d'excellents journalistes.
November 21, 2024 at 9:23 AM
Bonjour, bonjour, The Conversation France arrive sur Bluesky ! Ici, pas de breaking news tapageuses ni de buzz éphémères : on mise sur le fond, avec des articles écrits par des chercheurs et chercheuses qui savent de quoi ils parlent, en collaboration avec notre équipe d'excellents journalistes.
Reposted by Benoît Brilland
Results of the TAPIR trial: glucocorticoid discontinuation in GPA #ANCA vasculitis.
▶️ higher number of relapse at 6 months for the discontinuation group
▶️ but driven by minor relapses and by subgroup not treated but Rituximab.
Presented by Pr. Peter Merkel #ACR24 (acrabstracts.org/abstract/a-m...)
▶️ higher number of relapse at 6 months for the discontinuation group
▶️ but driven by minor relapses and by subgroup not treated but Rituximab.
Presented by Pr. Peter Merkel #ACR24 (acrabstracts.org/abstract/a-m...)
December 2, 2024 at 5:22 PM
Results of the TAPIR trial: glucocorticoid discontinuation in GPA #ANCA vasculitis.
▶️ higher number of relapse at 6 months for the discontinuation group
▶️ but driven by minor relapses and by subgroup not treated but Rituximab.
Presented by Pr. Peter Merkel #ACR24 (acrabstracts.org/abstract/a-m...)
▶️ higher number of relapse at 6 months for the discontinuation group
▶️ but driven by minor relapses and by subgroup not treated but Rituximab.
Presented by Pr. Peter Merkel #ACR24 (acrabstracts.org/abstract/a-m...)
Reposted by Benoît Brilland
Reduced GC dose in #ANCA vasculitis: @terrierben.bsky.social confirms PEXIVAS results in real life: no difference in death/ESKD. Larger composite criteria [see table] (that may be discussed) in favor of standard GC dose, especially for RTX patients and severe AKI ard.bmj.com/content/earl...
November 26, 2024 at 2:29 PM
Reduced GC dose in #ANCA vasculitis: @terrierben.bsky.social confirms PEXIVAS results in real life: no difference in death/ESKD. Larger composite criteria [see table] (that may be discussed) in favor of standard GC dose, especially for RTX patients and severe AKI ard.bmj.com/content/earl...
Reposted by Benoît Brilland
Welcome in @terrierben.bsky.social. The #vasculitis family is growing here on Bluesky!
Moving from Twitter? Looking for #vasculits #glomerulonephritis lovers?
Starter pack (work in progress): go.bsky.app/HFADD3c. Reply or DM to be added in the list!
Starter pack (work in progress): go.bsky.app/HFADD3c. Reply or DM to be added in the list!
November 24, 2024 at 3:49 PM
Welcome in @terrierben.bsky.social. The #vasculitis family is growing here on Bluesky!
Vasculitis folks are joining! Welcome in @lynnfussner.bsky.social @matsjunek.bsky.social
Moving from Twitter? Looking for #vasculits #glomerulonephritis lovers?
Starter pack (work in progress): go.bsky.app/HFADD3c. Reply or DM to be added in the list!
Starter pack (work in progress): go.bsky.app/HFADD3c. Reply or DM to be added in the list!
November 21, 2024 at 4:26 PM
Vasculitis folks are joining! Welcome in @lynnfussner.bsky.social @matsjunek.bsky.social
Moving from Twitter? Looking for #vasculits #glomerulonephritis lovers?
Starter pack (work in progress): go.bsky.app/HFADD3c. Reply or DM to be added in the list!
Starter pack (work in progress): go.bsky.app/HFADD3c. Reply or DM to be added in the list!
November 20, 2024 at 1:03 PM
Moving from Twitter? Looking for #vasculits #glomerulonephritis lovers?
Starter pack (work in progress): go.bsky.app/HFADD3c. Reply or DM to be added in the list!
Starter pack (work in progress): go.bsky.app/HFADD3c. Reply or DM to be added in the list!
Two recent reviews of #ANCA vasculitis with wonderful graphics, and for the first time I think, #PR3 🔹 and #MPO 🔸
phenotypes considered in parallel but SEPARATELY! A new era with individualized treatment is coming for sure!
🔹 pubmed.ncbi.nlm.nih.gov/38574742/
🔸 pubmed.ncbi.nlm.nih.gov/38574743/
phenotypes considered in parallel but SEPARATELY! A new era with individualized treatment is coming for sure!
🔹 pubmed.ncbi.nlm.nih.gov/38574742/
🔸 pubmed.ncbi.nlm.nih.gov/38574743/
Proteinase 3-specific antineutrophil cytoplasmic antibody-associated vasculitis
Proteinase 3 (PR3)-specific antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is one of two major ANCA-associated vasculitis variants a…
bit.ly
November 18, 2024 at 2:09 PM
Two recent reviews of #ANCA vasculitis with wonderful graphics, and for the first time I think, #PR3 🔹 and #MPO 🔸
phenotypes considered in parallel but SEPARATELY! A new era with individualized treatment is coming for sure!
🔹 pubmed.ncbi.nlm.nih.gov/38574742/
🔸 pubmed.ncbi.nlm.nih.gov/38574743/
phenotypes considered in parallel but SEPARATELY! A new era with individualized treatment is coming for sure!
🔹 pubmed.ncbi.nlm.nih.gov/38574742/
🔸 pubmed.ncbi.nlm.nih.gov/38574743/